Snapshot: On Tuesday, Shares of Catalyst Biosciences Inc (NASDAQ:CBIO), stock closed at $1.38. Trading volume recorded for this company was about 11,173.00 shares as contrast to its average volume of 27,164.00 shares. The share price plunged almost -5.48% in the last one month. The stock’s intraday range was $1.38 to $1.50.
News: In the liquidity ratio analysis; debt to equity ratio was 1.10. Catalyst Biosciences Inc, as of current trade, has shown weekly downbeat performance of -1.43 percent which was maintained at -5.48 percent in 1-month period. Catalyst Biosciences Inc (NASDAQ:CBIO), a leading biotechnology company focused on discovering and developing novel protease therapeutics for treatments of serious medical conditions in the fields of hemostasis and anti-complement, and CMC ICOS Biologics, Inc. (“CMC Biologics”), a global leader in clinical and commercial manufacturing of therapeutic proteins, today declared that they have reached a manufacturing agreement for the process transfer and cGMP manufacturing of CB 813d, Catalyst’s next-generation long-acting Factor VIIa product. Catalyst is developing CB 813d for the treatment of hemophilia A and B inhibitor patients.
“We selected CMC Biologics as our manufacturing partner for CB 813d because of their demonstrated technical expertise in producing commercial coagulation factor proteins and the quality of their cGMP operations,” stated Andrew Hetherington, Catalyst’s Vice President of Manufacturing Operations. “The successful transfer and manufacture of CB 813d is critical to meeting our clinical timelines as we advance our lead candidate towards a pivotal study.”
“We are developing CB 813d to potentially treat both acute bleeding episodes and allow for prophylactic treatment contrast to existing products and other therapies in development,” stated Nassim Usman, Ph.D., President & Chief Executive Officer of Catalyst. “We remain on track to initiate a Phase 2/3 clinical pivotal trial of CB 813d, our most advanced hemophilia product candidate, in 2017.”
“We are delighted that Catalyst has selected CMC Biologics as their contract manufacturing organization for CB 813d as they prepare for a key clinical efficacy trial,” stated Gustavo Mahler, Ph.D., President & Chief Executive Officer of CMC Biologics. “CMC has a great deal of experience manufacturing similar blood coagulation factor products and we look forward to manufacturing Catalyst’s next-generation Factor VIIa.”
Technical Analysis: CBIO institutional ownership is held at 56.40% while insider ownership was 0.20%. The company has the market capitalization of $15.35 Million. Its EPS was $4.75 while outstanding shares of the company were 11.43 Million. The company earned -$15.50 million in prior twelve months on revenue of $1.2Million.
